Innoviva, Inc. (INVA) stock
INVANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 14/3040% below fair value
$19.03+0.06 (+0.32%)
Close on Nov 13, 2026Market cap $1.37BP/E 9.7Yield –
Innoviva ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Innoviva's ebitda for the twelve months ending Jun 30, 2022 was $373.37M, up 4.0% year over year. For fiscal 2021 it was $388.94M, up 16.1% from the year before. The highest annual figure on record is $388.94M in fiscal 2021.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $388.94M | +16.1% |
| FY2020 | Dec 31, 2020 | $334.96M | +28.7% |
| FY2019 | Dec 31, 2019 | $260.23M | +3.2% |
| FY2018 | Dec 31, 2018 | $252.12M | +27.6% |
| FY2017 | Dec 31, 2017 | $197.59M | +60.7% |
| FY2016 | Dec 31, 2016 | $122.94M | +170.1% |
| FY2015 | Dec 31, 2015 | $45.51M | – |
| FY2014 | Dec 31, 2014 | -$21.75M | – |
| FY2013 | Dec 31, 2013 | -$25.34M | – |
| FY2012 | Dec 31, 2012 | -$21.90M | – |
| FY2011 | Dec 31, 2011 | -$102.15M | – |
| FY2010 | Dec 31, 2010 | -$71.99M | – |
| FY2009 | Dec 31, 2009 | -$75.82M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2022 | Jun 30, 2022 | $86.15M | -13.9% |
| Q1 FY2022 | Mar 31, 2022 | $81.23M | -2.1% |
| Q4 FY2021 | Dec 31, 2021 | $107.98M | +22.4% |
| Q3 FY2021 | Sep 30, 2021 | $98.01M | +11.5% |
| Q2 FY2021 | Jun 30, 2021 | $100.00M | +26.2% |
| Q1 FY2021 | Mar 31, 2021 | $82.94M | +4.2% |
| Q4 FY2020 | Dec 31, 2020 | $88.25M | +14.4% |
| Q3 FY2020 | Sep 30, 2020 | $87.89M | +37.1% |
| Q2 FY2020 | Jun 30, 2020 | $79.25M | +25.2% |
| Q1 FY2020 | Mar 31, 2020 | $79.58M | +42.9% |
| Q4 FY2019 | Dec 31, 2019 | $77.11M | -4.4% |
| Q3 FY2019 | Sep 30, 2019 | $64.11M | +4.9% |
| Q2 FY2019 | Jun 30, 2019 | $63.30M | -4.3% |
| Q1 FY2019 | Mar 31, 2019 | $55.71M | +26.1% |
| Q4 FY2018 | Dec 31, 2018 | $80.69M | +15.4% |
| Q3 FY2018 | Sep 30, 2018 | $61.13M | +40.5% |
| Q2 FY2018 | Jun 30, 2018 | $66.14M | +28.9% |
| Q1 FY2018 | Mar 31, 2018 | $44.16M | +34.5% |
| Q4 FY2017 | Dec 31, 2017 | $69.90M | +69.8% |
| Q3 FY2017 | Sep 30, 2017 | $43.52M | – |
| Q2 FY2017 | Jun 30, 2017 | $51.33M | – |
| Q1 FY2017 | Mar 31, 2017 | $32.84M | – |
| Q4 FY2016 | Dec 31, 2016 | $41.16M | – |
See a number that looks wrong?